Tenaya Therapeutics Partners with Alnylam to Develop Cardiovascular Disease Treatments
Tenaya Therapeutics (TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (ALNY) to discover novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases. "This multi-target collaboration underscores Tenaya's commitment to rigorous science and capitalizes on the proprietary capabilities that have contributed to the discovery and development of Tenaya's pipeline of candidates for cardiovascular conditions," said Faraz Ali, Chief Executive Officer of Tenaya Therapeutics. "By combining our modality agnostic target identification and validation capabilities with Alnylam's leadership in RNA interference therapeutics, we have an opportunity to advance candidates for novel genetic targets with the potential to create transformational medicines for patients with heart disease."
